StemRNA™ Clinical iPSCs
Quality Control & Characterization Data

Human induced pluripotent stem cells (iPSCs) can differentiate into a wide range of specialized cell types, enabling applications in regenerative medicine. REPROCELL’s StemRNA™ Clinical iPSC Seed Clones are generated using integration-free RNA reprogramming and undergo extensive quality control to ensure genetic integrity and suitability for downstream clinical manufacturing.

Quality Control Data of Typical StemRNA™ Clinical iPSC Clones

Typical quality control assays of Clinical StemRNA iPSC Lines. Typical quality control assays for Clinical StemRNA™ iPSC lines. To confirm suitability as starting material for clinical programs, each clonal line undergoes comprehensive validation, including cell count, post-thaw viability, sterility and mycoplasma testing, colony morphology and growth assessment, karyotyping, and pluripotency marker expression by flow cytometry. Functional pluripotency is further evaluated through directed differentiation into the three germ layers. Only clones meeting all batch release specifications are advanced to scale-up for GMP Master Cell Bank manufacturing. Data generated in-house.  

Efficient Neural Differentiation of StemRNA™ iPSCs 

Representative flow cytometry analysis of StemRNA™ clinical iPSC differentiation into neural cell types using rapid and conventional protocols. StemRNA iPSCs were sequentially differentiated into neural progenitor cells (NPCs), induced glia-restricted progenitor cells (iGRPs), and astrocytes. The upper panels show the rapid differentiation protocol using neural stem cell (NSC) medium supplemented with Smoothened agonist (SAG), platelet-derived growth factor-AA (PDGF-AA), and bone morphogenetic protein 4 (BMP-4) for 10 days, while the lower panels show the conventional 21-day protocol using NSC medium supplemented with SAG and PDGF-AA. Stage-specific marker expression is shown in red and corresponding isotype controls in green. Data generated in-house.

Typical iNK Cell Differentiation of
StemRNA™ Clinical iPSC Clones 

Expression of key NK cell surface markers in iNK cells derived from StemRNA™ clinical iPSC clones REPROCELL's clinical iPSCs were differentiated into iNK cells and characterized by flow cytometry. CD45⁺CD56⁺ NK cells expressed NKp44 (CD336), NKp46 (CD335), and NKG2D (CD314), demonstrating markers typical of mature, functional iNK cells. Data generated in collaboration with the Tokyo Metropolitan Institute of Medical Science, Japan. 

Contact our experts 

At REPROCELL, our scientists understand that your custom iPSC project must be as unique as your research. If you have any questions about how our Clinical iPSC Generation Service can help you advance your project, please make an inquiry using the form below.